Your browser doesn't support javascript.
loading
Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
Alexandre, Joachim; Salem, Joe-Elie; Moslehi, Javid; Sassier, Marion; Ropert, Camille; Cautela, Jennifer; Thuny, Franck; Ederhy, Stéphane; Cohen, Ariel; Damaj, Ghandi; Vilque, Jean-Pierre; Plane, Anne-Flore; Legallois, Damien; Champ-Rigot, Laure; Milliez, Paul; Funck-Brentano, Christian; Dolladille, Charles.
Afiliação
  • Alexandre J; PICARO Cardio-oncology Program, Department of Pharmacology, Normandie University, UNICAEN, CHU de Caen Normandie, EA 4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, F-14000 Caen, France.
  • Salem JE; Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, CIC-1421, INSERM, UMR ICAN 1166, Sorbonne Université, APHP.6 Cardio-oncology Program, F-75013 Paris, France.
  • Moslehi J; Department of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN 37240, USA.
  • Sassier M; Department of Medicine, Cardio-oncology Program, Vanderbilt University Medical Center, Nashville, TN 37240, USA.
  • Ropert C; Department of Pharmacology, CHU de Caen Normandie, PICARO Cardio-oncology Program, F-14000 Caen, France.
  • Cautela J; Department of Cardiology, CHU de Caen Normandie, F-14000 Caen, France.
  • Thuny F; Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Mediterranean University Cardio-Oncology Center, Hôpital Nord, Marseille 13915, France.
  • Ederhy S; Centre de Recherche Cardiovasculaire et Nutrition, Inserm 1263, Inra, Marseille 13915, France.
  • Cohen A; Groupe Méditerranéen de Cardio-Oncologie, Marseille 13915, France.
  • Damaj G; Oncosafety Network of the Early Phases Cancer Trials Center, Marseille 13915, France.
  • Vilque JP; Unit of Heart Failure and Valvular Heart Diseases, Department of Cardiology, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Mediterranean University Cardio-Oncology Center, Hôpital Nord, Marseille 13915, France.
  • Plane AF; Centre de Recherche Cardiovasculaire et Nutrition, Inserm 1263, Inra, Marseille 13915, France.
  • Legallois D; Groupe Méditerranéen de Cardio-Oncologie, Marseille 13915, France.
  • Champ-Rigot L; Oncosafety Network of the Early Phases Cancer Trials Center, Marseille 13915, France.
  • Milliez P; Hôpitaux Universitaires Paris-Est, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Service de cardiologie, Unico, Unité de cardio-oncologie APHP.6, GRC Groupe de recherche clinique en cardio oncologie, Inserm 856, Université Pierre et Marie Curie, Paris, France.
  • Funck-Brentano C; Hôpitaux Universitaires Paris-Est, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Service de cardiologie, Unico, Unité de cardio-oncologie APHP.6, GRC Groupe de recherche clinique en cardio oncologie, Inserm 856, Université Pierre et Marie Curie, Paris, France.
  • Dolladille C; Department of Hematology, CHU de Caen Normandie, F-14000 Caen, France.
Eur Heart J Cardiovasc Pharmacother ; 7(4): 312-320, 2021 07 23.
Article em En | MEDLINE | ID: mdl-32353110
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Antineoplásicos Idioma: En Ano de publicação: 2021 Tipo de documento: Article